Interní Med. 2001; 3(2): 75-79

Nízkomolekulární hepariny v terapii kardiovaskulárních nemocí

doc. MUDr. Jiří ©pác CSc
II. interní klinika FN u sv. Anny LF MU, Brno

Keywords: heparin, trombóza, akutní koronární syndrom.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pác J. Nízkomolekulární hepariny v terapii kardiovaskulárních nemocí. Interní Med. 2001;3(2):75-79.

Klinické a praktické nevýhody spojené s terapií nefrakcionovaným heparinem (NFH) vedly ke snaze pouľívat nízkomolekulárního heparinu (LMWH) jako alternativního způsobu léčby. Předpokládalo se, ľe výhodnějąí vlastnosti LMWH mohou zlepąit léčebné výsledky u řady trombotických onemocnění venosního a arteriálního systému. Na základě dnes provedených klinických studií lze říci, ľe LMWH jsou výhodnou terapeutickou alternativou NFH v léčbě tromboembolické nemoci, nestabilní anginy pectoris/non Q infarktu myokardu.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) IIB Trial. Circulation. 1999; 100: 1593-1601. Go to original source... Go to PubMed...
    2. Cohen M, Demers C, Gurfinkel EP et al(ESSENCE study group): A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in NonQ-wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52. Go to original source... Go to PubMed...
    3. Dolovich L. R, Ginsberg, J.S., Douketis J.D., Holbrook A.M.,, Cheah G.,: A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous Thromboembolism. Arch Intern Med 2000; 160: 181-188. Go to original source... Go to PubMed...
    4. The FRAXIS Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractioned heparin in the initial management of unstable angina or no Q wave myocardial infarction: FRAX.I.S (Fraxiparine in Ischaemic Syndrome). European Heart Journal, 20, 21, 1999, 1553-1562. Go to original source... Go to PubMed...
    5. Gonze M.D., Salartasch K., Sternbergh Ch., Baughman R.A., Leone-Bay A., Moneyz S.R.: Orally administerd unfractionated heparin with carrier agent is therapeutic for deep venous trombosis. Circulation, 2000, 10, 2658-2661. Go to original source... Go to PubMed...
    6. Hirsh J.: Low-molecular weight heparin. Circulation, 1998, 98, 1575-1582. Go to original source... Go to PubMed...
    7. Hirsh J., Raschke R., Warkentin T.E., Dalen J.E., Deykin D., Poller L.: Heparin: mechanism of action, pharmacokinetics, dosing consideration, monitoring, efficacy, and safety. Chest, 1995, 108, 4, 258S-275S. Go to original source... Go to PubMed...
    8. Klein W, Buchwald A, Hillis SE, et al. Comparison of low molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study. Circulation. 1997; 96: 61-68. Go to original source... Go to PubMed...
    9. Swahn E, Wallentin L, for the FRISC Study Group. Low- molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol. 1997; 80 (Suppl 5A): 25E-29E. Go to original source... Go to PubMed...
    10. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337: 688-698. Go to original source... Go to PubMed...
    11. Xiao,Z., Theroux, P.: Platalet activation with unfractioned heparin at therapeutic concentrations and comparisons with a low-molecular-wuight heparin and with a direct thrombin inhibitor. Circulation, 1998. 97, 251-256. Go to original source... Go to PubMed...
    12. Simnonneau G., Sors H., Charbonnier B., Beau B for the THESEE Group: A comparison of low molecular weight heparin with unfractioned heparin for acute pulmonary embolism.N. Engl. J. Med., 1997, 337, 663-669. Go to original source... Go to PubMed...
    13. ©pinar J., Novotný J., Mayer, J.: Hemokoagulační a hemorheologické poměry u srdečního selhání a moľnosti jejich ovlivnění glykaaminoglykany. Vnitřní lékařství, 1995, vol. 41, No. 1, s. 3-7. Go to PubMed...
    14. FRISC II Group: Invasive compared with non invasive treatment in unstable coronary artery disease: FRISC II propspective randomization multicentre study. Fragmin and Fast revascularization during InStability in Coronary artery disease. Lancet 1999, 354, 708-715. Go to original source...
    15. Samama M.M., Cohen A.T., et al for the Prophylaxis in Medical Patients with Enoxaparin Study Group: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New Engl. J.Med., 1999, 341, 793-800. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.